NCT05081167Phase 3Completed

A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)

Study sponsor: Relmada Therapeutics, Inc. · RLMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-09-13Actual
Enrollment · participants232Actual
Source updated2024-03-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview